Anticancer therapy targeting the ErbB family of receptor tyrosine kinases

被引：122

作者：

Slichenmyer, WJ

Fry, DW

机构：

[1] Pfizer Global Res & Dev, Dept Clin Oncol Dev, Ann Arbor, MI 48105 USA

[2] Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48105 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 05期

关键词：

D O I：

10.1053/sonc.2001.28557

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：67 / 79

页数：13

共 128 条

[1] Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol [J].

Aigner, A ;

Hsieh, SS ;

Malerczyk, C ;

Czubayko, F .

TOXICOLOGY, 2000, 144 (1-3) :221-228

[2]

Al Hazaa A, 2000, CLIN CANCER RES, V6, p4542S

[3] The ErbB receptors as targets for breast cancer therapy [J].

Albanell, J ;

Baselga, J .

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1999, 4 (04) :337-351

[4]

Azemar M, 2000, INT J CANCER, V86, P269, DOI 10.1002/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO

[5]

2-8

[6]

BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13

[7] The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer [J].

Bartlett, JMS ;

Langdon, SP ;

Simpson, BJB ;

Stewart, M ;

Katsaros, D ;

Sismondi, P ;

Love, S ;

Scott, WN ;

Williams, ARW ;

Lessells, AM ;

Macleod, KG ;

Smyth, JF ;

Miller, WR .

BRITISH JOURNAL OF CANCER, 1996, 73 (03) :301-306

[8] ZD1839 ('Iressa')1,2 as an anticancer agent [J].

Baselga, J ;

Averbuch, SD .

DRUGS, 2000, 60 (Suppl 1) :33-40

[9]

Baselga J, 2000, SEMIN ONCOL, V27, P20

[10] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

← 1 2 3 4 5 6 7 8 9 10 →